Status:
COMPLETED
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
Lead Sponsor:
GlaxoSmithKline
Conditions:
Non-Small-Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study was designed to determine how effective and safe Ispinesib is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a platinum-based chemothera...
Eligibility Criteria
Inclusion
- Must have received only one prior platinum-based chemotherapy regimen.
- Blood tests will be done to check if blood counts are adequate for taking part in the study.
Exclusion
- Received more than 1 chemotherapy regimen in the past or have less than adequate liver and kidney function.
- Females who are pregnant.
- Any unstable, pre-existing major medical condition or history of other cancers.
- Have received an investigational drug, chemotherapy, radiation treatment or surgery within 28 days prior to entering the study.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00085813
Start Date
December 1 2003
End Date
October 1 2005
Last Update
October 4 2010
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Scottsdale, Arizona, United States, 85259
2
GSK Investigational Site
Jacksonville, Florida, United States, 32224
3
GSK Investigational Site
Rochester, Minnesota, United States, 55905
4
GSK Investigational Site
Rochester, New York, United States, 14623